What do systematic reviews say?

Adaptive servo ventilation (ASV) plus best supportive care vs best supportive care alone or inactive control

The review found no eligible studies for this question.

• Non‐invasive positive pressure ventilation for central sleep apnoea in adults 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Adaptive servo ventilation (ASV) plus best supportive care vs best supportive care alone or inactive control

• Non‐invasive positive pressure ventilation for central sleep apnoea in adults 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Adaptive servo ventilation (ASV) plus best supportive care vs best supportive care alone or inactive control

• Non‐invasive positive pressure ventilation for central sleep apnoea in adults 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Adaptive servo ventilation (ASV) plus best supportive care vs best supportive care alone or inactive control

Adaptive servo ventilation (ASV) plus best supportive care showed no clear difference in all‐cause mortality ‐ up to 80 months Number of participants: 1355(2… compared with best supportive care alone or inactive control (low certainty).

• Non‐invasive positive pressure ventilation for central sleep apnoea in adults 2022 · Cochrane Headline outcomes only
  RR 0.56 [0.06, 4.93]
  Studies not reported
  Low

Adaptive servo ventilation (ASV) plus best supportive care vs best supportive care alone or inactive control

The review found no eligible studies for this question.

• Non‐invasive positive pressure ventilation for central sleep apnoea in adults 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 183 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 1 participants
  Low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 147 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 208 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  10 studies · 1250 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

Summary of findings table ‐ Systemic therapy showed no clear difference in change in grip strength from baseline to end of intervention compared with control (low certainty).

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  RR 1.08 [0.37, 3.17]
  1 study · 137 participants
  Low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 344 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

Summary of findings table ‐ Systemic therapy showed no clear difference in effect on discontinuation of aromatase inhibitors (AI) compared with control (low certainty).

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  RR 0.16 [0.01, 2.99]
  1 study · 147 participants
  Low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 44 participants
  Low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 1 participants
  Low

Summary of findings table ‐ Systemic therapy vs control

It is very uncertain whether summary of findings table ‐ Systemic therapy changes incidence of AIMSS compared with control (very low certainty).

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  RR 0.82 [0.63, 1.06]
  2 studies · 240 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  10 studies · 1099 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 295 participants
  Very low

Effects of high‐ vs low‐added sugar consumption

The review found no eligible studies for this question.

• High versus low‐added sugar consumption for the primary prevention of cardiovascular disease 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Effects of high‐ vs low‐added sugar consumption

The review found no eligible studies for this question.

• High versus low‐added sugar consumption for the primary prevention of cardiovascular disease 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found